Saccharides Science and Technology

Through the novel application of gap analysis methods in disease biotechnology, SST develops medications that serve as biochemical prostheses that bridge broken reaction pathways, create a normal physiological environment and programme the body to build a natural resistance to the disease. Unlike conventional treatments that act to directly suppress diseases rapidly often with adverse side- effects, SST’s products are designed to gradually correct genetic faults and biochemical mistakes that underlie these diseases. 

SST has been developing a series of patented pharmaceutical and medical device technologies and has found commercial success in its product, Amzylite F1.2, the first of its many upcoming diabetic oral medications.

Dr Tarig Arbab
Executive Director